Skip to Content
Morningstar
Get 14 Days Free

Colfax Corp CFX

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Colfax Posts Solid Q1 Results and Raises Low End of Full-Year 2021 Guidance; Increasing FVE

Analyst Note

| Krzysztof Smalec, CFA |

Narrow-moat-rated Colfax delivered solid first-quarter results, as its sales of $879 million and adjusted EPS of $0.44 both beat FactSet consensus estimates of $838 million and $0.40, respectively. Management raised the low end of its full-year 2021 adjusted EPS guidance range to $2.05 to $2.15 (from $2.00 to $2.15, previously). We’ve bumped our fair value estimate to $47.50 from $46.50, which reflects the firm’s solid execution, an improved outlook, and time value of money.

Read Full Analysis

Company Profile

Business Description

Colfax is a diversified technology firm that produces welding equipment and medical devices. Following the sale of its air and gas handling business in 2019, Colfax’s remaining portfolio is organized into two segments: fabrication technology and medical technology. Fabrication technology is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications, mostly marketed under the ESAB brand name. The medical technology segment makes medical devices, including orthopedic braces, reconstructive implants, and other products used for rehabilitation, physical therapy, and pain management. The company generated roughly $3.1 billion in revenue in 2020.

Contact
420 National Business Parkway, 5th Floor
Annapolis Junction, MD, 20701
T +1 301 323-9000
Sector Industrials
Industry Specialty Industrial Machinery
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2020
Stock Type Cyclical
Employees 15,400

Related

Premium Article
3 Stocks to Watch in 2020
These stocks are new to our coverage--and all have economic moats.
Susan Dziubinski
Fund Times
This Large-Growth Fund Isn't Afraid to Go Its Own Way
Silver-rated Akre Focus is a decisive and differentiated choice in a crowded category.
Alec Lucas
Quarter-End Insights
Our Outlook for Industrials Stocks
Recent U.S. economic data bodes well for industrial companies' near-term fortunes.
James Krapfel

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.